Every DEF 14A that PAVmed Inc. (PAVM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PAVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PAVM filings page.
PAVmed Inc. is calling a virtual annual stockholder meeting on June 24, 2026 at 10:00 a.m. Eastern. Stockholders will elect two Class A directors, approve amendments to the Employee Stock Purchase Plan (ESPP), and ratify CBIZ CPAs P.C. as independent auditor for 2026.
The ESPP proposal would raise shares available under the plan to 215,774 and increase the annual “evergreen” limit for future increases to up to 500,000 shares each January 1 through 2031. As of the April 27, 2026 record date, 7,272,739 shares of common stock were outstanding and eligible to vote.
PAVmed Inc. has called a virtual special meeting on March 27, 2026 to ask stockholders to approve several major capital and governance actions tied to a recent $30 million private placement and recapitalization completed on February 3, 2026.
The key item is approval, for Nasdaq Listing Rule 5635 purposes, of issuing common shares upon conversion of 60,000 shares of Series D Convertible Preferred Stock and in connection with a new senior secured convertible note due 2029. If all 60,000 Series D shares (including those underlying the warrants) convert at $6.50 per share, PAVmed expects to issue 9,230,769 common shares.
As of February 13, 2026, 1,496,696 shares of common stock were outstanding. Stockholders are also being asked to approve a charter amendment allowing removal of any director, with or without cause, by a majority of the outstanding voting power, an amendment to the 2014 Long-Term Incentive Equity Plan to raise the share pool by 1,500,000 shares to 1,713,517 shares, and authority to adjourn the meeting if needed to secure sufficient votes. The Board recommends voting “FOR” all proposals.
PAVmed Inc. (PAVM) called a virtual special meeting for December 5, 2025 to seek stockholder approval for a reverse stock split and an accompanying reduction in authorized common shares. The Board proposes a reverse split at a ratio between 1-for-10 and 1-for-30, with the exact ratio set at its discretion, and to reduce authorized common stock from 250,000,000 to 25,000,000. The reverse split is conditioned on consent of the Series C Preferred holder and includes rounding up for fractional shares to the next whole share.
The Board cites two main reasons: regain Nasdaq minimum bid compliance (common stock must close at or above $1 for at least ten consecutive business days by the current deadline) and broaden potential investor interest. Risks noted include uncertain price impact, potential liquidity reduction, and continued listing risks even if compliance is temporarily regained.
As of the October 23, 2025 record date, 28,085,405 common shares were outstanding and 21,323 Series C Preferred shares were outstanding (convertible into an estimated 3,117,133 common shares, subject to limits). A separate proposal would permit adjournment to solicit more proxies if needed.